Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140757 · ClinicalTrials.gov registry record
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
A clinical trial of Papillary Thyroid Cancer and Radiofrequency Ablation, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07140757: Recruiting study of Papillary Thyroid Cancer and Radiofrequency Ablation, sponsored by M.D. Anderson Cancer Center.
NCT07140757 is a study of Papillary Thyroid Cancer and Radiofrequency Ablation that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 438-participant average among 6 other Papillary Thyroid Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07140757, a study of Papillary Thyroid Cancer and Radiofrequency Ablation, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
Primary Outcome
This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.
Conditions Studied
Interventions
- OTHER Questionnaire
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2030-12-31 |
What NCT07140757 shows while recruiting
NCT07140757 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 438-participant average among 6 other Papillary Thyroid Cancer trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Papillary Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire is the first listed.
NCT07140757 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07140757 about?
NCT07140757 is a clinical study titled "Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers". To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
What is the current status of trial NCT07140757?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-08-18. Estimated completion is 2030-12-31.
What conditions does trial NCT07140757 study?
This clinical trial studies the following conditions: Papillary Thyroid Cancer, Radiofrequency Ablation, Low Risk.
What interventions are being tested in trial NCT07140757?
The interventions under investigation include: Questionnaire (OTHER).
Who is sponsoring clinical trial NCT07140757?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140757 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillary Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
RECRUITING
-
Studies on Tumors of the Thyroid
RECRUITING
-
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
ACTIVE NOT RECRUITING · Phase 1
-
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Radiofrequency Ablation of Papillary Thyroid Microcarcinoma
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI